This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

GUSTO II trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The GUSTO II study investigated the role of the thrombin-specific inhibitor hirudin in the treatment of myocardial infarction.

  • GUSTO-IIa - stopped early because of intracerebral haemorrhages (1)
    • re-initiated at lower dose of hirudin (see GUSTO-IIb)
    • Hirudin (vs. heparin)
      • greater incidence of stroke
      • even greater difference in those treated with thrombolysis
      • indication that APTT useful for predicting stroke risk in thrombolysis patients

  • GUSTO-IIb (Lower dose of Hirudin vs. GUSTO-IIa) (2)
    • Hirudin (vs. Heparin)
      • significantly reduced risk of death or MI at 24hr
      • no significant difference at 30 days

Reference:

  • Circulation. 1994 Oct;90(4):1631-7.
  • N Engl J Med. 1996 Sep 12;335(11):775-82.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.